- Home
- MIST vs GDL Comparison
MIST vs GDL Comparison
Compare MIST & GDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MIST | GDL |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.3M | 90.1M |
| IPO Year | 2019 | 2006 |
Fundamental Metrics
Financial Performance| Metric | MIST | GDL |
|---|---|---|
| Price | $0.73 | $8.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $5.57 | N/A |
| AVG Volume (30 Days) | ★ 934.7K | 16.3K |
| Earning Date | 11-16-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.02% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $125.44 | N/A |
| Revenue Next Year | $462.63 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.63 | $8.01 |
| 52 Week High | $3.06 | $8.67 |
Technical Indicators
Market Signals| Indicator | MIST | GDL |
|---|---|---|
| Relative Strength Index (RSI) | 46.95 | 47.64 |
| Support Level | $0.63 | $8.24 |
| Resistance Level | $1.42 | $8.52 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 58.27 | 56.25 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.